Beta Bionics, Inc. faces a securities class action over allegations that it concealed serious safety complaints involving its iLet automated insulin-delivery system and misrepresented the scope of regulatory remediation. The Law Offices of Frank R. Cruz reminded shareholders that investors who bought shares between July 30, 2025, and Feb. 24, 2026, have until Nov. 3, 2026, to seek appointment as lead plaintiff. The complaint alleges that an FDA Form 483 identified more than 18,000 complaints, including life-threatening hypoglycemic events that Beta Bionics allegedly failed to investigate or report to the FDA. The company is also the subject of an investigation by Hagens Berman, while prior investor notices from Kaplan Fox and Robbins LLP described related allegations and differing accounts of disclosure timing and share-price movements.